futuximab
mAbexperimental
Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1. — Wikipedia
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01117428)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1ANTAGONIST
EGFR antagonist
EGFR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFutuximab ↗
- ChEMBLCHEMBL2109388 ↗
Also known as
- 992 ds
- futuximab
- sym004
- sym-004
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05223673 | Phase 3 | Apr 21, 2022 | Servier, University of Campania Luigi Vanvitelli |
| NCT05162755 | Phase 1 | Oct 15, 2021 | Servier, The START Center for Cancer Care |
| NCT03717038 | Phase 3 | Feb 28, 2019 | Symphogen A/S, Universidad Autonoma de Barcelona |
| NCT03549338 | Phase 2 | Sep 30, 2018 | Symphogen A/S, University of Texas at Houston |
| NCT02965417 | Phase 2 | Dec 1, 2016 | Symphogen A/S |
| NCT02924233 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Symphogen A/S |
| NCT02568046 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | Symphogen A/S, Universidad Autonoma de Barcelona |
| NCT02540161 | Phase 2 | Feb 1, 2016 | Duke University, Symphogen A/S |
| NCT02083679 | Phase 1 | Jul 1, 2014 | Merck KGaA, Merck Serono |
| NCT02083653 | Phase 2 | Mar 1, 2014 | Symphogen A/S, Universidad Autonoma de Barcelona |
| NCT01955473 | Phase 1 | Oct 1, 2013 | Merck KGaA |
| NCT01417936 | Phase 2 | Jul 1, 2011 | Symphogen A/S |
| NCT01117428 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2010 | Symphogen A/S, Universidad Autonoma de Barcelona |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Symphogen A/S | For profit | 9 | 8 | 2 | 2010 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 4 | 0 | 2 | 2010 |
| Merck KGaA | For profit | 2 | 1 | 1 | 2013 |
| Servier | For profit | 2 | 2 | 2 | 2021 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Merck Serono | For profit | 1 | 1 | 1 | 2014 |
| The START Center for Cancer Care | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Campania Luigi Vanvitelli | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
9 organizations
Page 1 / 1